91 related articles for article (PubMed ID: 3545749)
21. [High dosage chemotherapy and peripheral blood stem cell transplantation in breast carcinoma].
Jentsch-Ullrich K; Höffken HG; Franke A
Zentralbl Chir; 1998; 123 Suppl 5():162-4. PubMed ID: 10063605
[TBL] [Abstract][Full Text] [Related]
22. Refining systemic therapy for early breast cancer: difficulties with subtraction.
Dodwell D; Thorpe H; Coleman R
Lancet Oncol; 2009 Aug; 10(8):738-9. PubMed ID: 19647192
[No Abstract] [Full Text] [Related]
23. Innumerable variations: combining biologics.
Sledge GW
Clin Breast Cancer; 2009 Feb; 9(1):7. PubMed ID: 19299233
[No Abstract] [Full Text] [Related]
24. Interpretation of results of chemotherapy trials in metastatic breast cancer.
J Clin Oncol; 1986 Feb; 4(2):258-61. PubMed ID: 3511185
[No Abstract] [Full Text] [Related]
25. Controversy over cancer chemotherapy in Japan.
Kawabata H; Ueno T
Lancet; 1999 Jun; 353(9169):2077. PubMed ID: 10376656
[No Abstract] [Full Text] [Related]
26. Chemotherapy in advanced breast cancer.
Gundersen S; Kvinnsland S
Acta Oncol; 1987; 26(2):81-7. PubMed ID: 3300710
[No Abstract] [Full Text] [Related]
27. Eligibility and extrapolation in cancer clinical trials.
Begg CB; Engstrom PF
J Clin Oncol; 1987 Jun; 5(6):962-8. PubMed ID: 3585451
[No Abstract] [Full Text] [Related]
28. Combination chemotherapy for metastatic breast cancer: reaching for the cure.
Overmoyer B
J Clin Oncol; 2003 Feb; 21(4):580-2. PubMed ID: 12586790
[No Abstract] [Full Text] [Related]
29. High-dose chemotherapy for advanced breast cancer.
Ahmad K
Lancet Oncol; 2006 Jan; 7(1):19. PubMed ID: 16408376
[No Abstract] [Full Text] [Related]
30. Early stopping of trials.
Hopf G
Lancet; 1997 Sep; 350(9081):891. PubMed ID: 9310635
[No Abstract] [Full Text] [Related]
31. Dose-response is alive and well.
DeVita VT
J Clin Oncol; 1986 Aug; 4(8):1157-9. PubMed ID: 3525764
[No Abstract] [Full Text] [Related]
32. Dose intensity: a critique of a critical review.
Hryniuk WM
J Clin Oncol; 1989 May; 7(5):681-4. PubMed ID: 2651583
[No Abstract] [Full Text] [Related]
33. Drug combinations: dangerous liaisons or great expectations?
Ratain MJ
Ann Oncol; 1999 Apr; 10(4):375-6. PubMed ID: 10370777
[No Abstract] [Full Text] [Related]
34. Progress in chemotherapy for metastatic breast cancer.
Sledge GW; Antman KH
Semin Oncol; 1992 Jun; 19(3):317-32. PubMed ID: 1609297
[No Abstract] [Full Text] [Related]
35. Side effects expected and experienced by women receiving chemotherapy for breast cancer.
Tierney AJ; Leonard RC; Taylor J; Closs SJ; Chetty U; Rodger A
BMJ; 1991 Feb; 302(6771):272. PubMed ID: 1998793
[No Abstract] [Full Text] [Related]
36. Attrition in metastatic breast cancer: a metric to be reported in randomised clinical trials?
Nuzzolese I; Montemurro F
Lancet Oncol; 2020 Jan; 21(1):21-24. PubMed ID: 31908294
[No Abstract] [Full Text] [Related]
37. The missing era of breast cancer chemotherapy.
Greenspan EM
J Clin Oncol; 1990 Mar; 8(3):565. PubMed ID: 2307993
[No Abstract] [Full Text] [Related]
38. Targeting the red-hot danger of inflammatory breast cancer.
Morris L
Nursing; 2010 Sep; 40(9):58-62. PubMed ID: 20714256
[No Abstract] [Full Text] [Related]
39. Chemotherapy in inflammatory breast cancer.
Denes AE
J Clin Oncol; 1987 May; 5(5):825. PubMed ID: 3572468
[No Abstract] [Full Text] [Related]
40. Chemotherapy: Maintenance therapy in breast cancer--many questions remain.
Martín M; López-Tarruella S
Nat Rev Clin Oncol; 2013 Jul; 10(7):370-2. PubMed ID: 23712182
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
